Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel

2005181 citationsJournal Article

Authors

Wolfgang Schuette · Carl-Thiem-Klinikum Cottbus

S. Nagel · Carl-Thiem-Klinikum Cottbus

Thomas Blankenburg · Carl-Thiem-Klinikum Cottbus

Christine Lautenschlaeger · Carl-Thiem-Klinikum Cottbus

K. Hans · Carl-Thiem-Klinikum Cottbus

Ernst-Wilhelm Schmidt · Klinikum St. Marien Amberg

Ina Dittrich

Abstract

Weekly docetaxel 35 mg/m2 demonstrated similar efficacy and better tolerability than standard 3-weekly docetaxel 75 mg/m2 and can be recommended as a feasible alternative second-line treatment option for patients with advanced NSCLC.

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 23, Issue 33, pp. 8389-8395

DOI: 10.1200/jco.2005.02.3739

Field-Weighted Citation Impact: 16.70